Bruce S. Colwill net worth and biography

Bruce Colwill Biography and Net Worth

Mr. Colwill has more than 25 years of financial leadership experience in both public and private companies. Prior to InMed, Mr. Colwill served as Chief Financial Officer of General Fusion Inc., a private clean energy company. Mr. Colwill was also

Chief Financial Officer at Entrée Resources Inc. (TSX: ETG; OTCQB: ERLFF), a mineral exploration company, from 2011 to 2016. He has held Chief Financial Officer roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Mr. Colwill has executed a successful IPO as well as multiple equity, debt and other structured financings. He has experience in both in-licencing and out-licencing biopharmaceutical products as well as in mergers and acquisitions. Mr. Colwill completed the Governance Professionals of Canada Education Program and received his GPC.D designation in July 2019. He holds a Bachelor of Business Administration from Simon Fraser University and is a member of the Chartered Professional Accountants of BC.

What is Bruce S. Colwill's net worth?: The estimated net worth of Bruce S. Colwill is at least $44,793.35 as of January 24th, 2022. Mr. Colwill owns 11,515 shares of InMed Pharmaceuticals stock worth more than $44,793 as of November 18th. This net worth approximation does not reflect any other investments that Mr. Colwill may own. Learn More about Bruce S. Colwill's net worth.
How do I contact Bruce S. Colwill?: The corporate mailing address for Mr. Colwill and other InMed Pharmaceuticals executives is , , . InMed Pharmaceuticals can also be reached via phone at 604-669-7207 and via email at [email protected]. Learn More on Bruce S. Colwill's contact information.
Has Bruce S. Colwill been buying or selling shares of InMed Pharmaceuticals?: Bruce S. Colwill has not been actively trading shares of InMed Pharmaceuticals during the past quarter. Most recently, on Monday, January 24th, Bruce Colwill bought 250 shares of InMed Pharmaceuticals stock. The stock was acquired at an average cost of $21.80 per share, with a total value of $5,450.00. Learn More on Bruce S. Colwill's trading history.
Who are InMed Pharmaceuticals' active insiders?: InMed Pharmaceuticals' insider roster includes Eric Adams (CEO), Bruce Colwill (CFO), and Shane Johnson (SVP). Learn More on InMed Pharmaceuticals' active insiders.
Are insiders buying or selling shares of InMed Pharmaceuticals?: During the last twelve months, InMed Pharmaceuticals insiders bought shares 2 times. They purchased a total of 3,955 shares worth more than $29,601.00. The most recent insider tranaction occured on February, 21st when Director Andrew Hull bought 1,875 shares worth more than $14,625.00. Insiders at InMed Pharmaceuticals own 1.9% of the company. Learn More about insider trades at InMed Pharmaceuticals.
Information on this page was last updated on 2/21/2024.

Bruce S. Colwill Insider Trading History at InMed Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/24/2022	Buy	250	$21.80	$5,450.00
9/28/2021	Buy	250	$35.40	$8,850.00

Bruce S. Colwill Buying and Selling Activity at InMed Pharmaceuticals

InMed Pharmaceuticals Company Overview

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Today's Range

Now: $3.89

$3.65

$4.29

50 Day Range

MA: $5.00

$4.04

$7.10

2 Week Range

Now: $3.89

$2.41

$15.70

Volume

23,107 shs

Average Volume

121,745 shs

Market Capitalization

$2.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36

📉 Warning: Market Crash Predicted - Secure Your Savings

From Behind the Markets | Ad

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>